Novavax to File Vaccine in U.K. and U.S. in Q2, CEO Says

The transcript discusses the process of filing vaccine data in the UK and US, highlighting the efficacy of the vaccine against severe cases and variants. It covers the adaptation of vaccines for booster shots, addressing vaccine nationalism, and the global manufacturing strategy. Safety concerns are also discussed, along with the timeline for future booster shots.

What are the plans for adapting the vaccine for booster shots as variants continue to emerge?

How does the speaker address concerns regarding the safety of vaccines, particularly in light of the AstraZeneca vaccine?

What is the timeline for potential booster shots, and what factors influence this timeline?